

**Table SI. Patient characteristics and response to dupilumab treatment of the patients presented here and published case reports**

		Sex	Age, years	Duration of prurigo	Atopy	Previous treatments	Maximum itch intensity (NRS)		DLQI		Prurigo control test	
							Before dupi	After dupi	Before dupi	After dupi	Before dupi	After dupi
This report	#1	M	41	14 months	Yes	Phototherapy, topical glucocorticoids, topical calcineurin inhibitors, antihistamines, gabapentin	10	3	25	4	4	14
	#2	F	45	3 years	Yes	Phototherapy, topical glucocorticoids, intralesional triamcinolone, pregabalin	10	0	29	2	0	17
	#3	M	52	5 years	Yes	Topical glucocorticoids, cyclosporine, gabapentin	10	4	19	12	2	10
Calugareanu et al., 2019 (11)	#1	F	30	9 years	Yes	Phototherapy, topical glucocorticoids, cryotherapy, antihistamines, dapsone, methotrexate, thalidomide, cyclosporine	9	0.5	-	-	-	-
Mollanazar et al., 2019 (12)	#1	F	50+	Unknown	No	Topical glucocorticoids, topical calcineurin inhibitors, mirtazapine	10	0	-	-	-	-
	#2	F	40+	Unknown	Yes	Topical glucocorticoids, topical calcineurin inhibitors, mirtazapine	10	0	-	-	-	-
	#3	F	30+	Unknown	No	Topical glucocorticoids, topical calcineurin inhibitors, mirtazapine	6	0	-	-	-	-
	#4	M	40+	Unknown	No	Topical glucocorticoids, topical calcineurin inhibitors, mirtazapine	9	0	-	-	-	-
Beck et al, 2019 (10)	#1	M	70+	15 years	-	Phototherapy, topical, systemic and intralesional glucocorticoids, antihistamines, gabapentin, dronabinol, Goeckerman therapy	7	0	-	-	-	-
	#2	F	50+	6 years	-	Antihistamines, gabapentin, Goeckerman therapy, pregabalin, thalidomide	8	1	-	-	-	-
	#3	M	50+	5 years	-	Cyclosporine, dronabinol, gabapentin, Goeckerman therapy, thalidomide	10	2	-	-	-	-

The time of assessment of symptoms and quality of life varied. Here, best treatment effects are shown, which were reached within 12–20 weeks of treatment in most patients. All patients received dupilumab at the recommended dose and approved for the treatment of patients with atopic dermatitis, i.e. 600 mg s.c. as a loading dose, followed by 300 mg s.c. every 2 weeks.

DLQI, Dermatology Life Quality Index; dupi, dupilumab; s.c.: subcutaneously.